Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Avanafil
Drug ID BADD_D00192
Description Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively lower risk of visual disturbances associated with off-target PDE6 inhibition.[L32113] It first received FDA approval on April 27, 2012,[L32058] with subsequent EMA approval in June 2013.[L32113]
Indications and Usage Avanafil is indicated for the treatment of erectile dysfunction.[L32058]
Marketing Status approved
ATC Code G04BE10
DrugBank ID DB06237
KEGG ID D03217
MeSH ID C553414
PubChem ID 9869929
TTD Drug ID D0Y5JC
NDC Product Code 53360-1141; 53360-1142; 62541-501; 14501-0090; 72384-752; 72384-753; 62541-502; 53360-1143; 62541-503; 69037-0019; 83137-0008; 72384-751
UNII DR5S136IVO
Synonyms avanafil | 4-((3-chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)-1-pyrrolidinyl)-N-(2-pyrimidinylmethyl)-5-pyrimidinecarboxamide | stendra
Chemical Information
Molecular Formula C23H26ClN7O3
CAS Registry Number 330784-47-9
SMILES COC1=C(C=C(C=C1)CNC2=NC(=NC=C2C(=O)NCC3=NC=CC=N3)N4CCCC4CO)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nasal congestion22.04.04.001--
Nasopharyngitis11.01.13.002; 22.07.03.002---
Nausea07.01.07.001--
Nephrolithiasis20.04.01.002--
Nervous system disorder17.02.10.001---
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.011--
Optic ischaemic neuropathy06.07.03.001; 17.04.05.006; 24.04.10.001---
Pain in extremity15.03.04.010--
Palpitations02.11.04.012--
Penile haemorrhage21.12.01.011; 24.07.03.018---
Penis disorder21.12.01.001---
Pollakiuria20.02.02.007--
Premature ejaculation19.08.01.002; 21.03.01.008---
Priapism21.03.01.005; 24.04.12.007---
Prostatic specific antigen increased13.23.01.003---
Pruritus23.03.12.001--
Pruritus genital21.10.01.002; 23.03.12.008---
Rash23.03.13.001---
Rhinorrhoea22.12.03.021--
Sinus congestion22.04.06.001---
Sinus headache17.14.01.002; 22.12.03.022--
Sinusitis11.01.13.005; 22.07.03.007--
Skin disorder23.03.03.007---
Somnolence17.02.04.006; 19.02.05.003--
Tachycardia02.03.02.007---
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urethral disorder20.07.01.002---
Urinary tract disorder20.08.01.001---
Urinary tract infection11.01.14.004; 20.08.02.001--
Vertigo04.04.01.003; 17.02.12.002--
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages